Experience

Davis Polk acted as special product counsel to the representative of the several underwriters in connection with the SEC-registered offering of 5,750,000 shares (including 750,000…

Davis Polk, together with Slaughter and May, is advising Shire plc in connection with a recommended cash and stock offer for Shire’s entire share capital by Takeda Pharmaceutical Company…

Davis Polk advised the joint book-running managers and representatives of the underwriters in the approximately $42.2 million initial public offering by ASLAN Pharmaceuticals Limited…

Davis Polk advised the joint global coordinators in connection with the initial public offering of CEVA Logistics AG on the SIX Swiss Exchange and concurrent private placement of…

Davis Polk acted as special product counsel to the representatives of the initial purchasers in connection with a Rule 144A offering by Five9, Inc. of an aggregate principal amount of …

Davis Polk advised Texas Instruments Incorporated on its SEC-registered debt offering of $1.3 billion aggregate principal amount of 4.150% notes due 2048. Texas Instruments is a global…

Davis Polk is advising Zhongsheng Group Holdings Limited in connection with its repurchase of HK$2.35 billion zero coupon convertible bonds due 2018 and the issuance of HK$3.925 billion…

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 5,000,000 shares of common stock of Unity Biotechnology, Inc. Unity…

Davis Polk advised the administrative agent, and the joint lead arrangers in connection with senior secured credit facilities provided to Black Knight InfoServ, LLC, consisting of a $1.25…

Davis Polk advised the joint global coordinators in the Hong Kong initial public offering of Ping An Healthcare and Technology Company Limited. The gross proceeds from the offering…